The global coronavirus pandemic is spurring a boom in health care investments, as companies large and small try to combat the infectious disease. Biotechs, in particular, have seen a boom in interest, as investors look to bet on what could be the next Moderna (MRNA).
Kedar Karkare, a health-care analyst at CB Insights, said 2020 was a record year for the sector.
“We had almost $42 billion invested into biopharmaceutical companies … across 1,851 deals,” Karkare said. That’s a 46% increase over 2019, but the number of deals was only 4% more than in 2019, indicating that more capital was spent making these deals, Karkare said.